Prescription drug · NDA
Tenormin (atenolol) NDC 24979-244
Atenolol 25 mg/1 · Tablet · Oral · Upsher-Smith Laboratories, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 24979-244-07 | 24979024407 | 90 TABLET in 1 BOTTLE (24979-244-07)Marketed from Aug 1, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tenormin
- Generic name (nonproprietary)
- atenolol
- Active ingredients
- Atenolol — 25 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 018240
- Marketing start
- Listing expires
- Other FDA classes
- Adrenergic beta-Antagonists (Mechanism)
- Identifiers
- Product ID 24979-244_c804fa73-5b5a-4e20-a1f5-6a13155df21fSPL ID c804fa73-5b5a-4e20-a1f5-6a13155df21fSPL set ID 6e850b1e-28a4-4ff8-8ed7-bb0b29faa28aRxCUI 150750, 152414, 197379, 197380, 197381, 201322UNII 50VV3VW0TIUPC 0324979246079, 0324979245072, 0324979244075
- Pharmacologic class
- beta-Adrenergic Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N424979024407followed by a unit qualifier and the quantityPackage 24979-0244-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Hypertension TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure g…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 018240
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tenorminatenolol | Atenolol 50 mg/1 | TabletOral | Upsher-Smith Laboratories, LLC | 24979-245 |
| Tenorminatenolol | Atenolol 100 mg/1 | TabletOral | Upsher-Smith Laboratories, LLC | 24979-246 |
| Tenorminatenolol | Atenolol 50 mg/1 | TabletOral | Almatica Pharma LLC | 52427-430 |